Join Now

Category Archives: BioUtah News

PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]

| Comments Off on PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

G2G Consulting Provides Updates from Washington D.C.

G2G Consulting Provides Updates from Washington D.C.

| Tagged | Comments Off on G2G Consulting Provides Updates from Washington D.C.

Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City

BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake City. Denali is using deep scientific and drug development expertise to discover and deliver effective biologic therapeutics to the brain. Co-founder and CEO, Ryan Watts, addressed the crowd who gathered to share the milestone with colleagues, public […]

| Comments Off on Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City

bioMérieux Recognized as Top 1% by S&P Global

bioMérieux Recognized as Top 1% by S&P Global

| Tagged | Comments Off on bioMérieux Recognized as Top 1% by S&P Global

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

| Tagged | Comments Off on Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat […]

| Comments Off on bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

E&I Ski Day 2025 Recap

E&I Ski Day 2025 Recap

| Comments Off on E&I Ski Day 2025 Recap

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

| Tagged | Comments Off on Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. This prestigious award provides Halia with a fully sponsored […]

| Comments Off on Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

| Comments Off on The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

First Patient Enrolled in Merit Medical’s PREEMIE Study

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

| Tagged | Comments Off on First Patient Enrolled in Merit Medical’s PREEMIE Study

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

| Tagged | Comments Off on iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia